Dudum Andrew

Dudum Andrew, CEO of Hims & Hers Health (HIMS), has demonstrated a pronounced selling bias in his insider transactions, with $94.97 million in total sales outweighing $1.22 million in purchases across 69 reported trades. His recent activity reinforces this trend, with five sales in 2025 and early 2026 accounting for substantial dispositions. On October 16, 2025, he executed multiple sales totaling approximately $6.74 million, including a single transaction valued at $2.47 million. The pattern continued on December 15, 2025, with a $3.29 million sale, followed by two significant dispositions on March 13, 2026—one for $2.24 million and another for $10.80 million. All transactions involve HIMS stock, reflecting Andrew’s exclusive focus on his company’s equity. The absence of recent purchases and the concentration of high-value sales suggest a consistent reduction in his position. While some filings show $0 value transactions—likely representing option exercises, grants, or other non-sale events—the monetization of shares dominates his activity. The scale and timing of these sales, particularly the eight-figure March 2026 transaction, underscore a sustained disposition strategy rather than routine diversification. No buys have been reported since earlier in the dataset, further emphasizing the one-directional nature of his recent trading.